Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
  • Login to see the comments

Lincl sleat lobel

  1. 1. A New and Effective method for intravenous Enyzyme replacement therapy: Late Infantile Batten Disease Yu Meng, David Sleat, Istvan Sohar, Peter Lobel. CABM, Rutgers University, Piscataway, NJ, 07076, lobel@cabm.rutgers.edu INTRODUCTION There is no effective therapy for LINCL. Our laboratory is evaluating treatment regimens in our mouse model to provide proof-of- principle for enzyme replacement therapy for LINCL. KEY PROJECTS 1. We have developed a new way of getting TPP1 from the bloodstream into the brain. This is more effective than any method discovered to date for any enzyme. 1. In principle, a non- invasive enzyme replacement therapy for LINCL is a realistic possibility. 1. These results provide strong support for further study of this remarkable delivery method. WHAT THIS MEANS FOR THERAPY Acknowledgements: This work was supported in part by a Johnson and Johnson Focused Giving Award and NIH R01 NS37918 to PL and a Batten Disease Support and Research Association fellowship to YM Enzyme replacement therapy has worked well for some lysosomal storage diseases. A synthetic form of the protein that is missing in patients is given to patients, and it travels to the lysosome and clears up storage material. 1 4 Cerebral Cortex LINCL mouse LINCL mouse treated with TPP1 and Peptide 6 LINCL is caused by the loss of a brain enzyme, tripeptidyl peptidase 1. Enzyme replacement therapy for LINCL is difficult because the blood-brain barrier prevents TPP1 administered into the blood entering the brain. To date, there are no good methods to beat the blood-brain barrier. 2 We have developed a new way to help TPP1 move from the bloodstream into the brain. When we inject mice with TPP1 and a special peptide into the tail vein, we can get 8-times higher than normal activity in the brain. When injected with the peptide, the TPP1 enters the neurons of the brain. Intravenous treatment of mice with TPP1 alone doesn’t increase lifespan. However, a single timepoint treatment with TPP1 and the peptide extends the lifespan of the LINCL mouse. Treatment 5 3 Wild-type mouse

×